Moneycontrol Be a Pro
Get App
Last Updated : Sep 20, 2019 03:24 PM IST | Source: Moneycontrol.com

Lupin rises 2% on USFDA approval for Levothyroxine Sodium Tablets

Levothyroxine Sodium Tablets USP was originally approved on January 18, 2019 as generic equivalent of SYNTHROID manufactured by ABBVIE Inc.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Lupin rose over 2 percent intraday on September 20 after company received nod from USFDA.

The company received approval for its sANDA for Levothyroxine Sodium Tablets USP from the United States Food and Drug Administration to market a generic equivalent of UNITHROID, manufactured by Jerome Stevens Pharmaceuticals Inc.

Levothyroxine Sodium Tablets USP was originally approved on January 18, 2019 as generic equivalent of SYNTHROID manufactured by ABBVIE Inc.

Close

With this sANDA approval, Levothyroxine Sodium Tablets are now AB rated (therapeutically equivalent) with Reference Listed Drugs, SYNTHROID and UNITHROID.

At 15:19 hrs Lupin was quoting at Rs 756.30, up Rs 14.95, or 2.02 percent on the BSE.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Sep 20, 2019 03:24 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant
Make every wish come true
10% CashBack on Apparel
10% CashBack on Electronics
Swipe & Win iPhone 11 every hour